- Home
- HOWL vs IFRX Comparison
HOWL vs IFRX Comparison
Compare HOWL & IFRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HOWL
- IFRX
- Stock Information
- Founded
- HOWL 2017
- IFRX 2007
- Country
- HOWL United States
- IFRX Germany
- Employees
- HOWL N/A
- IFRX N/A
- Industry
- HOWL Biotechnology: Pharmaceutical Preparations
- IFRX Biotechnology: Pharmaceutical Preparations
- Sector
- HOWL Health Care
- IFRX Health Care
- Exchange
- HOWL Nasdaq
- IFRX Nasdaq
- Market Cap
- HOWL 47.1M
- IFRX 53.5M
- IPO Year
- HOWL 2021
- IFRX 2017
- Fundamental
- Price
- HOWL $1.33
- IFRX $0.86
- Analyst Decision
- HOWL Strong Buy
- IFRX Strong Buy
- Analyst Count
- HOWL 3
- IFRX 4
- Target Price
- HOWL $8.33
- IFRX $7.75
- AVG Volume (30 Days)
- HOWL 199.3K
- IFRX 210.6K
- Earning Date
- HOWL 08-14-2025
- IFRX 08-07-2025
- Dividend Yield
- HOWL N/A
- IFRX N/A
- EPS Growth
- HOWL N/A
- IFRX N/A
- EPS
- HOWL N/A
- IFRX N/A
- Revenue
- HOWL N/A
- IFRX $191,224.00
- Revenue This Year
- HOWL N/A
- IFRX N/A
- Revenue Next Year
- HOWL N/A
- IFRX $1,276.37
- P/E Ratio
- HOWL N/A
- IFRX N/A
- Revenue Growth
- HOWL N/A
- IFRX 54.36
- 52 Week Low
- HOWL $0.60
- IFRX $0.71
- 52 Week High
- HOWL $4.18
- IFRX $2.82
- Technical
- Relative Strength Index (RSI)
- HOWL 58.20
- IFRX 50.72
- Support Level
- HOWL $1.12
- IFRX $0.78
- Resistance Level
- HOWL $1.29
- IFRX $0.86
- Average True Range (ATR)
- HOWL 0.08
- IFRX 0.07
- MACD
- HOWL 0.01
- IFRX 0.00
- Stochastic Oscillator
- HOWL 75.00
- IFRX 58.33
About HOWL Werewolf Therapeutics Inc.
Werewolf Therapeutics Inc is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer. It is leveraging its proprietary PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Its INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment or TME.
About IFRX InflaRx N.V.
InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent, and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.